| abstract |
Disclosed is the use of (a) a compound of formula A which includes compounds such as (S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one, wherein R is selected from the group consisting of H, halo, and C1-C6 alkyl; R’ is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient, and (b) a monoclonal antibody, in the manufacture of a medicament for the treatment of a hematological malignancy in a human, and wherein the medicament is formulated for separate, sequential, or simultaneous administration of (a) and (b). |